NO20072931L - Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva - Google Patents

Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva

Info

Publication number
NO20072931L
NO20072931L NO20072931A NO20072931A NO20072931L NO 20072931 L NO20072931 L NO 20072931L NO 20072931 A NO20072931 A NO 20072931A NO 20072931 A NO20072931 A NO 20072931A NO 20072931 L NO20072931 L NO 20072931L
Authority
NO
Norway
Prior art keywords
treatment
temozolomide
patient
dosing regimen
cancer based
Prior art date
Application number
NO20072931A
Other languages
English (en)
Norwegian (no)
Inventor
Chen Zong
Benjamin Winograd
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36168622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072931(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20072931L publication Critical patent/NO20072931L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)
    • G01N2333/91017—Methyltransferases (general) (2.1.1.) with definite EC number (2.1.1.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20072931A 2004-11-09 2007-06-08 Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva NO20072931L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62625804P 2004-11-09 2004-11-09
PCT/US2005/040449 WO2006052976A2 (fr) 2004-11-09 2005-11-07 Methodes de traitement

Publications (1)

Publication Number Publication Date
NO20072931L true NO20072931L (no) 2007-08-03

Family

ID=36168622

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072931A NO20072931L (no) 2004-11-09 2007-06-08 Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva

Country Status (13)

Country Link
US (2) US20060100188A1 (fr)
EP (1) EP1830845A2 (fr)
JP (2) JP2008519584A (fr)
CN (1) CN101098696A (fr)
AU (1) AU2005304672B2 (fr)
BR (1) BRPI0517976A (fr)
CA (1) CA2585446A1 (fr)
MX (1) MX2007005581A (fr)
NO (1) NO20072931L (fr)
NZ (1) NZ554831A (fr)
TW (1) TW200630089A (fr)
WO (1) WO2006052976A2 (fr)
ZA (1) ZA200703716B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101172104B (zh) * 2002-02-22 2013-04-03 默沙东公司 抗肿瘤剂,特别是替莫唑胺的药物制剂,其制备方法和用途
EP1830845A2 (fr) * 2004-11-09 2007-09-12 Shering Corporation Regime de dosage ameliore de temozolomide pour le traitement du cancer fonde sur le niveau de mgmt du patient
US20070111979A1 (en) * 2005-11-07 2007-05-17 Walter Robert Bishop Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule
EP1976515A2 (fr) * 2006-01-17 2008-10-08 Abbott Laboratories Polythérapie faisant appel à des inhibiteurs de la parp
CN103751186B (zh) 2006-04-05 2016-08-24 欧科生医股份有限公司 药物制剂：8-[{1-(3,5-双-(三氟甲基)苯基)-乙氧基}-甲基]-8-苯基-1,7-二氮杂-螺[4.5]癸-2-酮的盐及用其治疗的方法
HUE028908T2 (en) 2006-04-05 2017-01-30 Opko Health Inc The hydrochloride salt of 8 - [{1- (3,5-bis (trifluoromethyl) phenyl) ethoxy} methyl] -8-phenyl-1,7-diazaspiro [4.5] decan-2-one, and process
US20070264672A1 (en) * 2006-05-09 2007-11-15 Bimalendu Dasmahapatra Development of a novel assay for mgmt (methyl guanine methyl transferase)
AR061618A1 (es) * 2006-06-26 2008-09-10 Schering Corp Formas de dosificacion unitaria de temozolomida
CA2686848A1 (fr) * 2007-05-08 2008-11-20 Schering Corporation Procedes de traitement par formulations intraveineuses comprenant du temozolomide
US20080319039A1 (en) * 2007-06-25 2008-12-25 Jacqueline Rose Bersch Unit dosage forms of temozolomide
US8435972B2 (en) * 2010-09-02 2013-05-07 Emory University Method for the treatment of central nervous system cancers and compositions related thereto
US9630966B2 (en) * 2013-04-17 2017-04-25 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CA2982205A1 (fr) 2015-04-10 2016-10-13 David W. Andrews Procedes et compositions de traitement de cancers et d'amelioration de l'immunite therapeutique par reduction selective des monocytes m2 immunomodulateurs
CN110408694A (zh) * 2018-04-26 2019-11-05 胤安国际（辽宁）基因科技股份有限公司 评估替莫唑胺在治疗脑胶质瘤患者的敏感性的新方法
WO2020198587A1 (fr) * 2019-03-28 2020-10-01 Thomas Jefferson University Méthodes de traitement de cancers à l'aide d'acides nucléiques antisens
WO2023113538A1 (fr) * 2021-12-17 2023-06-22 숙명여자대학교산학협력단 Polythérapie à base de griséofulvine pour le traitement d'une tumeur cérébrale
CN119318654A (zh) * 2024-12-16 2025-01-17 中国医学科学院基础医学研究所 氟达拉滨和替莫唑胺联用在治疗脑胶质瘤中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260291A (en) * 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US5876146A (en) * 1995-10-27 1999-03-02 General Electric Company Apparatus and methods for repairing jet pump diffusers in a nuclear reactor
US5786146A (en) * 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6017704A (en) * 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5939098A (en) * 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
CN1345240A (zh) * 1999-03-30 2002-04-17 先灵公司 用替莫唑胺改善癌症治疗
US6346524B1 (en) * 1999-03-30 2002-02-12 Schering Corporation Cancer treatment with temozolomide
WO2001085221A2 (fr) * 2000-05-12 2001-11-15 Duke University Reactifs et methodes de dosage des niveaux de $i(0)6-alkylguanine-adn alkyltransferase $i(in vivo) (agt)
US6773897B2 (en) * 2000-09-29 2004-08-10 The Johns Hopkins University School Of Medicine Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents
EP1332208A2 (fr) * 2000-10-30 2003-08-06 Gene Logic, Inc. Acides nucleiques partiellement bicatenaires, leurs procedes de production et leur utilisation
ATE502030T1 (de) * 2000-11-20 2011-04-15 Takeda Pharmaceutical Imidazolderivate, verfahren zu deren herstellung und deren verwendung
WO2004038404A2 (fr) * 2002-10-28 2004-05-06 Pharmacia Italia Spa Procede permettant d'optimiser l'efficacite therapeutique de la nemorubicine
US7718364B2 (en) * 2003-03-25 2010-05-18 John Wayne Cancer Institute DNA markers for management of cancer
EP1830845A2 (fr) * 2004-11-09 2007-09-12 Shering Corporation Regime de dosage ameliore de temozolomide pour le traitement du cancer fonde sur le niveau de mgmt du patient
US20070111979A1 (en) * 2005-11-07 2007-05-17 Walter Robert Bishop Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule

Also Published As

Publication number Publication date
AU2005304672B2 (en) 2010-03-11
US20090247598A1 (en) 2009-10-01
TW200630089A (en) 2006-09-01
EP1830845A2 (fr) 2007-09-12
BRPI0517976A (pt) 2008-10-21
CA2585446A1 (fr) 2006-05-18
US20060100188A1 (en) 2006-05-11
WO2006052976A3 (fr) 2006-08-17
MX2007005581A (es) 2007-05-23
CN101098696A (zh) 2008-01-02
JP2011121960A (ja) 2011-06-23
NZ554831A (en) 2009-10-30
ZA200703716B (en) 2008-09-25
WO2006052976A2 (fr) 2006-05-18
JP2008519584A (ja) 2008-06-12
AU2005304672A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
NO20072931L (no) Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
LU93321I2 (fr) Ibrutinib, ou un sel pharmaceutiquement acceptable de celui-ci
WO2006008639A8 (fr) Traitement combine pour malignites non hematologiques par anticorps anti -ogf-1r
TR200001891T2 (tr) ASPB28- İnsan ensülini ve kullanımı.
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
NO20074109L (no) Intravenose formuleringer av PDE-5 inhibitorer
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
ATE451340T1 (de) Deuterierte catecholaminderivate sowie diese verbindungen enthaltende arzneimittel
EA200501565A1 (ru) Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса
MA31227B1 (fr) Composition pharmaceutique renfermant du phloroglucinol et du paracetamol.
TW200616606A (en) Treatment and prevention of multi-drug resistance
SE0102887D0 (sv) New formulation
SE0203817D0 (sv) New composition
NO20075508L (no) Stannsoporfinpreparater og administrering
IS8373A (is) Notkun oxkarbasepíns til að meðhöndla sársauka vegna sykursýkisfjöltauga-kvilla og til að bæta svefn
WO2007093519A3 (fr) Nouveau regime d'ibandronate
TNSN06305A1 (en) Treatment regimen for camptothecin derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application